On November 20, Gronhek reported that jiangsu hengrui pharmaceuticals (600276.SH) rose over 6% to 50.46 yuan, with a trading volume expanding to 5.15 billion yuan and a total market value of 321.8 billion yuan. According to the latest report from shanxi, the leading innovative drugs firm is accelerating commercial commercialization, with its metabolism and autoimmunity pipelines entering a harvest period. The company has already launched 17 innovative drugs, with nearly 10 new drug NDAs accepted. According to the employee stock ownership plan, an additional 15 new drug NDA applications will be made from 2024 to 2026, with the concentration of newly launched drugs providing growth momentum. This is the first coverage, giving a "buy - A" rating. (Gronhek)